52.87 0.00 (0.00%)
After hours: 4:07PM EST
|Bid||52.89 x 2200|
|Ask||52.90 x 1000|
|Day's Range||52.37 - 53.41|
|52 Week Range||27.79 - 66.01|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 5, 2020 - Feb 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.35|
(Bloomberg) -- Security researchers discovered vulnerabilities in cheap smartwatches for children that make it possible for strangers to override parental controls and track kids.Rapid7 Inc., a cybersecurity firm based in Boston, purchased three smartwatches on Amazon.com, costing from $20 to $35, according to Deral Heiland, research lead for IoT technology. He said the models -- GreaSmart Children’s SmartWatch, Jsbaby Game Smart Watch and SmarTurtle Smart Watch for Kids -- were picked randomly from dozens for sale on Amazon and marketed as appropriate for grade school-aged kids.All three devices offer location tracking, messaging and chat features. They were manufactured in China and shared nearly identical hardware and software. They also had similar security issues, Rapid7 found.The watches let authorized users view and change configuration details by texting the watch directly with certain commands. In practice, this didn’t work and “unlisted numbers could also interact with the watch,” Rapid7 said in a report.This security issue could be fixed with a vendor-supplied firmware update, but “such an update is unlikely to materialize given that the providers of these devices are difficult to impossible to locate,” the cybersecurity firm added.The watches have a default password of “123456,” but one of the watch’s manuals doesn’t mention the password, according to the researchers. Another mentioned the password in a blog but not in its printed material. The third doesn’t characterize the numbers as a password nor does it provide instructions on how to change it, according to the researchers.“Given an unchanged default password and a lack of SMS filtering, it is possible for an attacker with knowledge of the smartwatch phone number to assume total control of the device, and therefore use the tracking and voice chat functionality with the same permissions as the legitimate user (typically, a parent),” Rapid7 said in its report.An unauthorized user could shut off all the safety protocols a parent had set up on the smartwatch, Heiland said.Rapid7 said its researchers weren’t able to contact the sellers nor what they believe is the manufacturer of the watches, a Chinese company called 3g Electronics Co. The company didn’t respond to a message from Bloomberg News seeking comment.The GreaSmart Children’s SmartWatch is no longer for sale on Amazon, according to Rapid7. GreaSmart, Jsbaby, SmarTurtle didn’t respond to a requests for comment. Oltec, a merchant that sells the SmarTurtle watch on Amazon, didn’t respond to a message sent via Amazon’s site.“Consumers that are concerned with the safety, privacy, and security of their IoT devices and the associated cloud services are advised to avoid using any technology that is not provided by a clearly identifiable vendor, for what we hope are obvious reasons,” Rapid7 warned in its report.To contact the reporter on this story: Andrew Martin in New York at email@example.comTo contact the editors responsible for this story: Tom Giles at firstname.lastname@example.org, Alistair Barr, Andrew PollackFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Is Rapid7 Inc (NASDAQ:RPD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus […]
BOSTON, Dec. 05, 2019 -- Rapid7, Inc. (NASDAQ: RPD), a leading provider of security analytics and automation, today announced that management will be presenting at the Barclays.
BOSTON, Dec. 03, 2019 -- Rapid7, Inc. (NASDAQ: RPD), a leading provider of security analytics and automation, today announced findings from a new commissioned study conducted.
This allows security teams to purchase and deploy the solution in hours, so that they can get visibility across their cloud or hybrid environment and accelerate their threat detection and response. Security teams tasked with protecting organizations as they migrate to the cloud often struggle with the amount of time and work it takes to replace an outdated or on-premises SIEM. When purchasing InsightIDR through AWS Marketplace, security teams gain visibility across their entire network, and can easily begin collecting data from AWS, endpoints, on-premises networks, other cloud providers, and SaaS applications within hours.
Global investment bank, RBC Capital, is one of the finance world’s heavy hitters. It is the 5th largest in North America, and with 70 offices in 15 countries around the world, it has a stellar reputation. This international reputation and the financial clout that comes with it, naturally attracts top talent, and top talent can bring home the bacon, so to speak. It is no wonder then that RBC leads TipRanks’ list of Top Performing Research Firms.With this in mind, we decided to take a look at some of the recent stock recommendations from RBC analysts, specifically ones with potential for 30%+ gains ahead.Agile Therapeutics (AGRX)Agile Therapeutics shares took a nosedive in late October after briefing documents released by the FDA expressed concern regarding the “effectiveness in proportion to its safety,” of Twirla, the company’s contraceptive patch, ahead of an AdCom review. As it happens, the review panel voted in favor of approval, which coincidentally, sent the stock skyrocketing.Following the AdCom’s positive outcome, RBC surveyed physicians to better understand the experts’ view on Twirla. The results echoed those of the AdCom, and with the PDUFA set for November 16, the impression is that Twirla will most likely be granted approval by the FDA.RBC analyst Randall Stanicky noted, “We could see approval this week or alternatively a potential ~3month delay as FDA works through labeling; either way we think shares at these levels show attractive near-term upside… Our survey of 40 OB/GYNs was surprisingly bullish on desire for Twirla as a contraceptive option; this increases our conviction that there is a place for it in the market.”As a result, Stanicky reiterates a Buy rating on AGRX along with a $5.00 price target, which implies a whopping upside of 130% from current levels. (To watch Stanicky’s track record, click here)How does Stanicky's bullish bet weigh in against the Street? It appears the analyst is not the only one enthusiastic on this healthcare stock, with TipRanks analytics demonstrating AGRX as a Strong Buy. This breaks down into 5 "buy" ratings in the last three months. With a return potential of over 100%, the stock’s consensus target price stands at $4.50. (See Agile stock analysis on TipRanks)Rapid7 (RPD)Cyber-security firm, Rapid7, provides data and analytics software to help organizations keep their networks safe from malicious cyber threats. Basically, it does what it says on the tin and reduces risk across a connected environment.Last week, Rapid7 delivered stronger quarterly results than expected, with annualized recurring revenue (ARR) growing by 43% on top of 17% customer growth. Overall, the company posted earnings of one cent per share on revenue of $83.16 million, beating the loss of 3 cents and revenue of $80.12 million analysts expected. Therefore, the company has now raised 2019 revenue guidance from $319 million to $323.5 million.Citing Rapid7 as a favorite SMID-cap, RBC’s 5-star analyst Matthew Hedberg believes that although estimates have gone higher, they still look beatable. Hedberg noted, “ARR growth is the key metric, as management expects it to remain at or above 30% through 2020. While the stock has performed well, we continue to believe it represents an attractive investment… In addition to new customer additions, we believe 2020 should see the cross-sale of additional products like InsightIDR and InsightAppSec and longer-term InsightConnect. This value generation was shown in ARR per customer, which grew 22% y/y… Our estimates move higher, but we still believe upside remains through 2020…”This has led Hedberg to keep his Buy rating along with a price target of $81.00. With RPD currently trading at $51.08, this provides upside of about 60%. (To watch Hedberg’s track record, click here).Looking at the consensus breakdown, the cyber-security firm has amassed 8 Buys and 1 Hold in the last three months, making Rapid7 a Strong Buy. The average stock-price forecast is $65.50. Not quite as bullish as Hedberg, this target still provides upside of 28% from its current price. (See Rapid7 price targets and analyst ratings on TipRanks)Aprea Therapeutics (APRE)Aprea Therapeutics is a Boston, Massachusetts-based biopharma focused on developing and bringing to market novel cancer therapeutics that reactivate mutant tumor suppressor protein p53. Aprea’s main drug candidate is APR-246, a small molecule in clinical development designed to treat various forms of cancer with TP53 mutations. These are found in half of all cancers. Through its unique design, APR-246 is able to restore immune defenses and promote apoptosis of cancer cells.The company will present updated data from its phase II trial in December, and it believes APR-246 will be a first-in-class therapy if approved by regulators.RBC’s Gregory Renza agrees, saying, “We believe APRE’s small molecule p53 reactivator pipeline in oncology, led by APR-246, has ample potential given the data to date and catalyst setup expected over the year. We see APRE emerging as a competitive player in the oncology space, especially in severe TP53 populations where unmet need is high, and believe in its potential for long-term share appreciation as the programs continue to de-risk… If approved, we see prospects of $800M WW peak sales in MDS at a ~35% POS, driving 2/3 of our valuation.”Renza initiated coverage with a bullish call and set a price target of $33.00, indicating upside of over 32%. (To watch Renza’s track record, click here)It’s a tad quiet when it comes to analyst coverage, with only two other analysts currently providing ratings for APRE, both recommending a Hold. With an average price target of $26.33 providing a modest 5% upside from its current price, the biopharma newbie ranks as a Moderate Buy. (See Aprea price targets and analyst ratings on TipRanks)
Corey Thomas became the CEO of Rapid7, Inc. (NASDAQ:RPD) in 2012. First, this article will compare CEO compensation...
Rapid7 (RPD) delivered earnings and revenue surprises of 133.33% and 3.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Stock futures signal further gains for the market rally. RingCentral, Everbridge and Adobe earnings news offer hope for the software sector.
Annualized recurring revenue (ARR) of $310.2 million, an increase of 43% year-over-yearRevenue of $83.2 million, 33% year-over-year growth and customer growth of 17%.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
Rapid7 (RPD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rapid7, Inc. (RPD), a leading provider of security analytics and automation, today announced it has been recognized by Forrester Research, Inc. as a Leader in The Forrester Wave™: Vulnerability Risk Management, Q4 2019 report. Rapid7’s vulnerability risk management solution, InsightVM, received the highest possible score in nine out of the 14 criteria.
BOSTON, Oct. 10, 2019 -- Rapid7, Inc. (NASDAQ: RPD), a leading provider of security analytics and automation, today announced that the company will release its third quarter.
It hasn't been the best quarter for Rapid7, Inc. (NASDAQ:RPD) shareholders, since the share price has fallen 23% in...
LEXINGTON, Mass., Sept. 25, 2019 -- Mimecast Limited (NASDAQ: MIME), a leading email and data security company, today announced Rapid7 has joined the Cyber Alliance Program.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
CFO of Rapid7 Inc (30-Year Financial, Insider Trades) Jeffrey Kalowski (insider trades) sold 37,500 shares of RPD on 08/15/2019 at an average price of $53.73 a share. Continue reading...
CEO of Rapid7 Inc (30-Year Financial, Insider Trades) Corey E. Thomas (insider trades) sold 20,000 shares of RPD on 08/07/2019 at an average price of $55.24 a share. Continue reading...